In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Advanced Cancer Therapeutics LLC

Latest From Advanced Cancer Therapeutics LLC

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010

Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.


Start-Up Previews (09/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Biotechs Target Cancer Metabolism," features profiles of Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals. Plus these Start-Ups Across Health Care: AlloCure, ArisGen, HistoSonics and NeuraviBiotechnology.

Recent Financings of Private Companies (09/2010)

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.

Advanced Cancer Therapeutics LLC

Advanced Cancer Therapeutics LLC is developing candidates against two cancer-metabolism targets. The first is PFKFB3, an enzyme that is believed to be a key player in glucose metabolism. Preclinical results suggest the compound inhibits tumors’ ability to consume glucose for growth and metastasis. ACT is also advancing a set of potential inhibitors against another key metabolic target called choline kinase, which is responsible for generating phosphocholine, one of the most important enzymes associated with choline metabolism and cell proliferation.

See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Advanced Cancer Therapeutics LLC
  • Senior Management
  • Randall B Riggs, Pres. & CEO
    Gilles H Tapolsky, PhD, CSO
  • Contact Info
  • Advanced Cancer Therapeutics LLC
    Phone: (502) 589-6404
    429 W. Muhammad Ali Blvd.
    Ste. 600
    Louisville, KY 40202